Physician profile
George Thomas
NPI 1073746046
$124,160.52
in general payments reported to CMS, 2019-2025
62 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,368 · 2020: $8,421 · 2021: $31K · 2022: $29K · 2023: $21K · 2024: $19K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Food and Beverage: $10K · Education: $32.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,898.50 |
| Food and Beverage | $10,348.43 |
| Education | $32.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $60,023.27 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $51,153.57 | 2019-2022 | |
| Amgen INC. | $1,844.27 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,604.33 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,335.18 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $1,263.99 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,033.35 | 2019-2025 | Jardiance |
| Pfizer INC. | $893.24 | 2019-2025 | |
| Galderma Laboratories, L.P. | $478.86 | 2019-2025 | |
| Glaxosmithkline, LLC. | $323.97 | 2020-2022 | |
| Organon LLC | $321.04 | 2022-2025 | Nexplanon |
| Linus Health, INC. | $275.47 | 2024 | Core Cognitive Evaluation |
| Bayer Healthcare Pharmaceuticals INC. | $264.84 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $235.28 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $231.12 | 2020-2021 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.